U.S. Markets close in 1 hr 26 mins

# Does SS&C Technologies Holdings Inc’s (NASDAQ:SSNC) PE Ratio Warrant A Buy?

SS&C Technologies Holdings Inc (NASDAQ:SSNC) is currently trading at a trailing P/E of 31.2x, which is lower than the industry average of 34.9x. While this makes SSNC appear like a great stock to buy, you might change your mind after I explain the assumptions behind the P/E ratio. In this article, I will deconstruct the P/E ratio and highlight what you need to be careful of when using the P/E ratio. Check out our latest analysis for SS&C Technologies Holdings

### What you need to know about the P/E ratio

The P/E ratio is one of many ratios used in relative valuation. It compares a stock’s price per share to the stock’s earnings per share. A more intuitive way of understanding the P/E ratio is to think of it as how much investors are paying for each dollar of the company’s earnings.

P/E Calculation for SSNC

Price-Earnings Ratio = Price per share ÷ Earnings per share

SSNC Price-Earnings Ratio = \$50.09 ÷ \$1.605 = 31.2x

On its own, the P/E ratio doesn’t tell you much; however, it becomes extremely useful when you compare it with other similar companies. We preferably want to compare the stock’s P/E ratio to the average of companies that have similar features to SSNC, such as capital structure and profitability. A quick method of creating a peer group is to use companies in the same industry, which is what I will do. At 31.2x, SSNC’s P/E is lower than its industry peers (34.9x). This implies that investors are undervaluing each dollar of SSNC’s earnings. As such, our analysis shows that SSNC represents an under-priced stock.

### Assumptions to watch out for

Before you jump to the conclusion that SSNC is the perfect buying opportunity, it is important to realise that our conclusion rests on two assertions. Firstly, our peer group contains companies that are similar to SSNC. If this isn’t the case, the difference in P/E could be due to other factors. For example, if you compared higher growth firms with SSNC, then its P/E would naturally be lower since investors would reward its peers’ higher growth with a higher price. The second assumption that must hold true is that the stocks we are comparing SSNC to are fairly valued by the market. If this does not hold true, SSNC’s lower P/E ratio may be because firms in our peer group are overvalued by the market.

### What this means for you:

Since you may have already conducted your due diligence on SSNC, the undervaluation of the stock may mean it is a good time to top up on your current holdings. But at the end of the day, keep in mind that relative valuation relies heavily on critical assumptions I’ve outlined above. Remember that basing your investment decision off one metric alone is certainly not sufficient. There are many things I have not taken into account in this article and the PE ratio is very one-dimensional. If you have not done so already, I urge you to complete your research by taking a look at the following:

1. Future Outlook: What are well-informed industry analysts predicting for SSNC’s future growth? Take a look at our free research report of analyst consensus for SSNC’s outlook.
2. Past Track Record: Has SSNC been consistently performing well irrespective of the ups and downs in the market? Go into more detail in the past performance analysis and take a look at the free visual representations of SSNC’s historicals for more clarity.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned.

Motley Fool

### 2 More Marijuana Stocks Are Moving to the NYSE

This year, we've witnessed GW Pharmaceuticals gain approval in the U.S. for the first cannabis-derived drug, and we watched as Vermont legalized recreational marijuana use entirely through the legislative process. This began with Cronos Group at the end of February, when it chose to list its shares on the Nasdaq. It was followed just a few months later by Canopy Growth Corp., which became the first marijuana stock to list on the NYSE.

• Finance
Bloomberg

### Companies Say They're Ready to Move Supply Chains From China

U.S. President Donald Trump imposed a 10 percent tariff on \$200 billion of Chinese imports in September -- following an earlier round of tariffs on \$50 billion of goods -- and promised to raise the duty to 25 percent in January. "We’re pro-actively taking action," Todd Bluedorn, chief executive officer of the Texas-based HVAC company, told analysts during an Oct. 22 earnings call.

Benzinga

### A Preview Of Juniper Networks Q3 Earnings

Juniper Networks (NYSE: JNPR) releases its next round of earnings this Tuesday, Oct. 23. Here's Benzinga's essential guide to Juniper Networks' Q3 earnings report. Earnings and Revenue Juniper Networks EPS will likely be near 44 cents while revenue will

Motley Fool

### Why Investors Are Paying a Premium for These 3 Biotech Stocks

Amarin stock exploded in September because it looks like Vascepa will become the next go-to drug for this enormous population. During the 8,179-patient Reduce-It trial, patients given Vascepa in addition to their normal statin treatments were 25% less likely to suffer a major cardiovascular event such as a heart attack. Over the past year, Amarin Corporation actually lost \$92 million because sales of Vascepa just haven't kept pace with operating expenses.

Motley Fool

### Why Tesla Stock Jumped Tuesday

Shares of electric-car company Tesla (NASDAQ: TSLA) popped on Tuesday, rising as much as 7.5%. The stock's rise comes after the electric-car company scheduled its earnings report about a week earlier than usual with just two days' notice, leading to some speculation that the automaker may have achieved its goal to become profitable during the quarter. Citron Research, which had previously encouraged investors to short Tesla stock, is now reversing its stance on the stock.

Motley Fool

### 5 Deeply Discounted Value Stocks That Haven't Been This Cheap in at Least a Decade

October has been a wake-up call for investors that the stock market won't go up in a straight line, even if we'd like it to. Sure, Bank of America (NYSE: BAC) has seen its stock catapult higher from its Great Recession lows, but its forward P/E of 9.8 would represent a more-than-decade low for the stock.

### Larry Kudlow details plans for Trump's middle-income tax cut

President Trump commits to a new middle-income tax reduction of 10 percent to be voted on after Election Day; Director of the National Economic Council Larry Kudlow explains.

### The stock market's 'dead cat bounce' is over and the rolling bear market is making a comeback, Morgan Stanley says

The stock market may have bounced back following its sharp sell-off at the beginning of October, but Morgan Stanley says the selling is going to pick back up soon. Tread carefully in tech and consumer discretionary, Morgan Stanley warns.

• Finance
CNBC

### Here's the tax bite on \$1.6 billion Mega Millions and \$620 million Powerball jackpots

Strategies can be employed to reduce the amount of your win that is taxed, although they are best explored with the help of an experienced tax advisor. While it's anyone's guess who will end up winning the Mega Millions and Powerball jackpots, there's at least one guaranteed recipient of a chunk of the loot — the IRS. With the Mega Millions jackpot at \$1.6 billion and Powerball's top prize at \$620 million, that tax bill will be hefty even if the winner employs strategies to reduce their taxable income.

• News
MarketWatch

### Suze Orman missed the point of retirement, and that’s why she went back to work

Suze Orman did a smackdown of the FIRE (Financial Independence/Retire Early) movement on Paula Pant’s podcast. Coach Carson posted a balanced, informative response, appreciating Suze’s admonition to be sure you have enough for a risk-free retirement. Suze enumerated a string “what can go wrong” scenarios as evidence that early retirement (on less than \$10 million) leaves you vulnerable when life hands you lemons — a whole tree of lemons.

Zacks

### Will L Brands (LB) Beat Estimates Again in Its Next Earnings Report?

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? L Brands (LB), which belongs to the Zacks Retail - Apparel and Shoes industry, could be a great candidate to consider. When looking at the last two reports, this owner of Victoria's Secret, Bath & Body Works and other chain stores has recorded a strong streak of surpassing earnings estimates.

• Finance
Motley Fool

### Is the New Energy Transfer LP a Buy?

Last week, Energy Transfer LP (NYSE: ET) emerged on the scene after the former Energy Transfer Equity completed the acquisition of its affiliate Energy Transfer Partners in a unit-for-unit exchange that simplified this complex midstream franchise. The transaction also created a much stronger company that has the financial resources to fund a significant slate of expansion projects. The new Energy Transfer is a behemoth in the midstream sector.

Reuters

### Helios and Matheson to spin off MoviePass into a separate company

The data company, which took a controlling stake in MoviePass in December, now owns a 92 percent stake in the business. Helios and Matheson said it would create a new unit MoviePass Entertainment Holdings Inc that would take ownership of the shares of MoviePass Inc and other film related assets held by the company. MoviePass allows subscribers to watch three movies a month for a flat fee of \$9.95 and get discounts on additional movie tickets.

Motley Fool

### Parsing Visa's Big Quarterly Dividend Hike

The ubiquitous financial services player Visa (NYSE: V) isn't exactly an income stock -- its dividend yield has fairly consistently been below 1% for years. Which raises two interesting questions for MarketFoolery host Chris Hill and senior analyst Jason Moser. In this segment from MarketFoolery, they discuss Visa's cash cow structure, its stock repurchases, and the M&A possibilities it thus far seems to be ignoring.

• COL
CNBC Videos

### These stocks may be sacrificed in a cold war with China

Jim Cramer says the escalation in the United States' trade war with China could end in an outright cold war that debilitates parts of the stock market.

• News
CNBC

### Here's how much money you should have saved by 50

Fidelity, the nation's largest retirement-plan provider, recommends having the equivalent of six times your annual salary saved. To get to that number, Fidelity recommends saving 15 percent of your annual income. Make sure to invest these funds instead of leaving them in a traditional low-interest savings account.

Motley Fool

### Why These 3 Top Marijuana Stocks Slumped Today

With earnings season hitting a crescendo this week, investors are looking closely at the specific prospects for certain corners of the market, and that's contributing to disparities among the various major benchmarks followed most often by investors. Amid the crosscurrents, marijuana stocks took particularly hard hits, and New Age Beverages (NASDAQ: NBEV), Tilray (NASDAQ: TLRY), and Canopy Growth (NYSE: CGC) were among the worst performers on the day. All three of these stocks have given back some of their gains following the long-awaited legalization of recreational cannabis in the Canadian market last week. In the month leading up to the Oct. 17 start date for legal cannabis sales, New Age Beverages tripled in value, while Tilray had more than doubled since the end of August, and Canopy Growth had seen more modest gains of between 10% and 20%.

• News
MarketWatch

### Dow tumbles nearly 550 points at lows amid corporate outlook, China selloff

It was a punishing start for stocks Tuesday as investors reacted negatively to quarterly results from a handful of blue chips and the cessation of a two-day rebound for China’s embattled stock market, reviving fresh questions about global economic growth prospects. The Dow Jones Industrial Average (DJIA) 548.62 points at its low and remained was recently 460 points, or 1.8%, at 24,862. The S&P 500 (SPX) fell 55 points, or 2%, to 2,696, retreating below a psychological and technical mark at 2,700, while the Nasdaq Composite Index (COMP) slid gave up 177 points, or 2.4%, to 7,291.

Motley Fool

### What the Market Missed in Kinder Morgan Inc.'s Results

Kinder Morgan (NYSE: KMI) can't seem to catch a break these days. Despite its completing what management dubbed a "momentous" quarter, shares of the natural gas pipeline giant barely budged this week. It was a head-scratching outcome considering that its financial results came in well above its guidance, which the market seems to have completely missed.

Motley Fool

### Why Nektar Therapeutics Crashed 17.2% Today

After delivering a disappointing update on NKTR-214 in cancer patients this summer, Nektar Therapeutics' (NASDAQ: NKTR) shares have been struggling. The company didn't report any news today, so a negative report issued by Plainview LLC this month may be to blamed for its 17.2% tumble today. In February, Bristol-Myers Squibb (NYSE: BMY) inked a blockbuster deal to license rights to NKTR-214 following positive data last year for NKTR-214's use alongside Bristol-Myers' Opdivo.

• Politics
Bloomberg

### Trump’s Tax Push to Help Middle Class Could Help Top Earners Too

It’s still unclear how Trump will propose to reduce the tax burden on middle-class Americans, but one of the most straightforward ways would be to lower rates by 10 percent for single filers making up to \$82,500. U.S. income tax rates are graduated and income dollars get taxed in chunks as they move up through the brackets -- which means wealthy Americans would also get to apply the reduced rate on their first dollars of income. “A millionaire gets the same size tax cut,” said Kyle Pomerleau, an economist at the conservative Tax Foundation.

Zacks

### Amgen (AMGN) Q3 Earnings Preview: What to Look Out For

Amgen (AMGN) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2018. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on October 30.

• Finance
Yahoo Finance

### Stocks plunge, Dow drops more than 300 points

US equities took a nosedive Tuesday, extending a rout in global stocks. The Dow (^DJI) slid 1.31%, or 332.69 points, as of 1:01 p.m. ET, as major manufacturers Caterpillar and 3M posted disappointing financial results. The S&P 500 (^GSPC) fell 1.32%,

• Finance
Market Realist

### What to Expect from Bristol-Myers Squibb’s Q3 Earnings

Bristol-Myers Squibb (BMY) is expected to report its third-quarter earnings on October 25. Analysts expect Bristol-Myers Squibb’s revenues to increase 8.87% from \$5.25 billion in the third quarter of 2017 to \$5.72 billion in the third quarte of 2018. In the last four quarters, Bristol-Myers Squibb’s revenue growth has been 3.93%–10.89%.